Abstract
BackgroundAccording to several neoadjuvant studies, pertuzumab combined with chemotherapy based on trastuzumab is effective in early and advanced HER2-positive breast cancer (BC). Based on the highest rate (51.9%) of complete...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have